STAT+: Novo Nordisk launches high-dose Wegovy
Tuesday, April 7, 2026 – Wednesday April 8 - Insurers score Medicare Advantage wins, the obesity drug race continues, and other biotech news from The Readout
FDA Approves Foundayo, a Wegovy Alternative GLP-1 Pill for Weight Loss
Tuesday, April 7, 2026 – Wednesday April 8 - The FDA has approved a new once-daily GLP-1 pill for weight loss. Image Credit: Healthline/Photo by Eli Lilly
Federal regulators have approved the GLP-1 tablet Foundayo for use in weight management.
Experts say having another weight loss medication in pill form could help people stick to a weight management regimen.
AAD: Ixekizumab + Tirzepatide Boosts Psoriatic Arthritis Outcomes More Than Ixekizumab Monotherapy
Monday, April 6, 2026 – MONDAY, April 6, 2026 -- Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or obesity, according to a study presented at the annual meeting of the...
A Beginner Strength Training Workout for People on GLP-1s
Monday, April 6, 2026 – Tuesday, April 7 - Combat muscle loss with this 7-move routine.
Ixekizumab + Tirzepatide boosts psoriatic arthritis outcomes more than Ixekizumab monotherapy
Monday, April 6, 2026 – Tuesday, April 7 - Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or obesity, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.
GLP-1 agonist drugs show digestive side effects but may help fight infections
Monday, April 6, 2026 – Tuesday, April 7 - Originally developed to treat diabetes, a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now stepping into the spotlight as weight loss drugs. A recent umbrella review draws attention to safety concerns regarding the use of this GLP medication, alongside a mix of potential benefits.
Dulaglutide or Tirzepatide? Worldwide Biopharma Changes
Saturday, April 4, 2026 – Sunday, April 5 - (MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of Texas Tech Health El Paso, look at the top medical...
Wegovy Pill Demonstrated Greater Weight Loss Than Orforglipron and Lower Odds of Stopping Medication Due to Side Effects in a New Indirect Comparison to be Presented at Obesity Medicine Association 2026
Thursday, April 2, 2026 – Friday, April 3 - PLAINSBORO, NJ and BAGSVÆRD, Denmark, April 2, 2026 /PRNewswire/ -- Novo Nordisk will present the ORION study at the upcoming Obesity Medicine Association’s annual conference in San Diego showing that Wegovy® (semaglutide) tablets 25...
Foundayo vs. Wegovy: How Do the New Weight Loss Pills Compare?
Thursday, April 2, 2026 – Friday, April 3 - Their effectiveness also depends on what else you do when you take them.
Wegovy Maker Launches Lower-Cost Subscription Plans
Thursday, April 2, 2026 – THURSDAY, April 2, 2026 — A popular weight loss drug may soon be more affordable for some people.
Danish pharmaceutical company Novo Nordisk has launched a subscription program for its obesity treatment Wegovy, offering lower and more...